 |
|
Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1
Laurent Mandelbrot, MD;
Aline Landreau-Mascaro, MS;
Claire Rekacewicz, MD;
Alain Berrebi, MD;
Jean Louis Bénifla, MD;
Marianne Burgard, PhD;
Eric Lachassine, MD;
Béatrice Barret, MD;
Marie-Laure Chaix, PhD;
André Bongain, MD;
Nicole Ciraru-Vigneron, MD;
Catherine Crenn-Hébert, MD;
Jean-François Delfraissy, MD;
Christine Rouzioux, PhD;
Marie-Jeanne Mayaux, BA;
Stéphane Blanche, MD;
for the Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group
JAMA. 2001;285:2083-2093.
Context Zidovudine reduces maternal-infant transmission of human immunodeficiency virus 1 (HIV-1) infection by two thirds. Combination antiretroviral therapies are potentially more effective prevention.
Objectives To assess the safety of perinatal lamivudine-zidovudine therapy, especially in children, and its effects on viral load, acquisition of drug resistance, and maternal-infant transmission of HIV-1 in a nonbreastfeeding population.
Design and Setting The Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study, an open-label, nonrandomized intervention trial conducted in the context of an ongoing observational cohort study in 48 sites in France.
Patients A total of 445 HIV-1–infected pregnant women were enrolled as the study cohort from February 1997 to September 1998; controls consisted of 899 pregnant women who had received zidovudine monotherapy in May 1994 to February 1997 as standard care.
Intervention The study cohort received lamivudine in addition to the standard Pediatric AIDS Clinical Trial Group 076 Study zidovudine prophylaxis regimen. Lamivudine was initiated in women at 32 weeks' gestation through delivery at 150 mg twice per day orally; children received lamivudine, 2 mg/kg twice per day for 6 weeks.
Main Outcome Measures HIV-1 infection status and tolerance of therapy in children through age 18 months; maternal plasma HIV-1 RNA levels through 6 weeks after delivery.
Results The transmission rate in the study group was 1.6% (7/437; 95% confidence interval [CI], 0.7%-3.3%). In a multivariable analysis, transmission in the study group was 5-fold lower than in controls. In the study group, maternal plasma HIV-1 RNA level was less than 500 copies/mL at delivery in 74%; the median decrease was 1.24 (range, -1.63 to 3.40) log10 copies/mL. The M184V lamivudine resistance mutation was detected at 6 weeks after delivery in specimens from 52 of 132 women. The most frequent serious adverse events in children were neutropenia and anemia, requiring blood transfusion in 9 children and premature treatment discontinuation in 19. Two uninfected children died at age 1 year from neurologic complications related to mitochondrial dysfunction.
Conclusions Lamivudine-zidovudine may be effective in preventing maternal-infant HIV transmission. However, severe adverse effects and emergence of resistance to lamivudine occurred. Thus, the role of this combination therapy in this setting is as yet unclear, and further research involving a variety of strategies is needed to definitively ascertain its utility for preventing maternal-infant HIV transmission.
Author Affiliations: Department of Obstetrics-Gynecology, Hôpital Cochin (Dr Mandelbrot), Department of Obstetrics-Gynecology, Hôpital Bichat (Dr Bénifla), Departments of Virology (Drs Burgard, Chaix, and Rouzioux) and Pediatric Immunology (Dr Blanche), Hôpital Necker, and Department of Obstetrics-Gynecology, Hôpital Lariboisière (Dr Ciraru-Vigneron), Paris, France; Institut National de la Santé et de la Recherche Médicale Unité 292 (Mss Landreau-Mascaro and Mayaux and Drs Rekacewicz and Barret) and Department of Internal Medicine, Hôpital Kremlin-Bicêtre (Dr Delfraissy), Kremlin-Bicêtre, France; Department of Obstetrics-Gynecology, Hôpital La Grave, Toulouse, France (Dr Berrebi); Department of Obstetrics-Gynecology, Hôpital Jean Verdier, Bondy, France (Dr Lachassine); Department of Obstetrics-Gynecology, Hôpital l'Archet 2, Nice, France (Dr Bongain); and Department of Obstetrics-Gynecology, Hôpital Louis Mourier, Colombes, France (Dr Crenn-Hébert).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Combination Prophylaxis for Prevention of Maternal-Infant HIV Transmission: Beyond 076
Nathan Shaffer
JAMA. 2001;285(16):2129-2131.
EXTRACT
| FULL TEXT
April 25, 2001
JAMA. 2001;285(16):2141-2142.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Evaluation and Management of the Infant Exposed to HIV-1 in the United States
Havens et al.
Pediatrics 2009;123:175-187.
ABSTRACT
| FULL TEXT
HIV Testing and Prophylaxis to Prevent Mother-to-Child Transmission in the United States
Committee on Pediatric AIDS
Pediatrics 2008;122:1127-1134.
ABSTRACT
| FULL TEXT
Cost-effectiveness estimates for antenatal HIV testing in the Netherlands
Rozenbaum et al.
Int J STD AIDS 2008;19:668-675.
ABSTRACT
| FULL TEXT
Population Pharmacokinetics of Lamivudine in Human Immunodeficiency Virus-Exposed and -Infected Infants
Tremoulet et al.
Antimicrob. Agents Chemother. 2007;51:4297-4302.
ABSTRACT
| FULL TEXT
Routine antenatal HIV testing: the responses and perceptions of pregnant women and the viability of informed consent. A qualitative study
de Zulueta and Boulton
J. Med. Ethics 2007;33:329-336.
ABSTRACT
| FULL TEXT
Declines in Low Birth Weight and Preterm Birth Among Infants Who Were Born to HIV-Infected Women During an Era of Increased Use of Maternal Antiretroviral Drugs: Pediatric Spectrum of HIV Disease, 1989-2004
Schulte et al.
Pediatrics 2007;119:e900-e906.
ABSTRACT
| FULL TEXT
Serum Lactate Levels in Infants Exposed Peripartum to Antiretroviral Agents to Prevent Mother-to-Child Transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 Study, Abidjan, Ivory Coast
Ekouevi et al.
Pediatrics 2006;118:e1071-e1077.
ABSTRACT
| FULL TEXT
Evidence behind the WHO Guidelines: Hospital Care for Children: What Antiretroviral Agents and Regimens are Effective in the Prevention of Mother-to-child Transmission of HIV?
Nightingale and Dabis
J Trop Pediatr 2006;52:235-238.
FULL TEXT
Prevention of mother-to-child transmission of HIV infection: Ukraine experience to date
Malyuta et al.
Eur J Public Health 2006;16:123-127.
ABSTRACT
| FULL TEXT
Encouraging results despite complexity of multidisciplinary care of HIV-infected women using assisted reproduction techniques
Ohl et al.
Hum Reprod 2005;20:3136-3140.
ABSTRACT
| FULL TEXT
Prenatal Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force
Chou et al.
ANN INTERN MED 2005;143:38-54.
ABSTRACT
| FULL TEXT
Efavirenz Reclassified as FDA Pregnancy Category D
AIDS Clin Care 2005;2005:3-3.
FULL TEXT
Advances in the Prevention of Perinatal HIV-1 Transmission
Shetty and Maldonado
NeoReviews 2005;6:e12-e25.
FULL TEXT
A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil
Lambert et al.
Sex. Transm. Infect. 2003;79:448-452.
ABSTRACT
| FULL TEXT
Mother to Child Transmission of HIV
Newberry and Kelsey
Journal of Pharmacy Practice 2003;16:182-190.
ABSTRACT
Assisted reproduction techniques for HIV serodiscordant couples: 18 months of experience
Ohl et al.
Hum Reprod 2003;18:1244-1249.
ABSTRACT
| FULL TEXT
Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F1/Tk+/- mice treated neonatally with zidovudine and lamivudine
Von Tungeln et al.
Carcinogenesis 2002;23:1427-1432.
ABSTRACT
| FULL TEXT
Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1
Church
Pediatrics 2002;110:469-470.
FULL TEXT
Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission: A Randomized Trial
Dorenbaum et al.
JAMA 2002;288:189-198.
ABSTRACT
| FULL TEXT
Antiretroviral Therapy during Pregnancy and the Risk of an Adverse Outcome
Tuomala et al.
NEJM 2002;346:1863-1870.
ABSTRACT
| FULL TEXT
Combination antiretroviral therapy in 100 HIV-1-infected pregnant women
Bucceri et al.
Hum Reprod 2002;17:436-441.
ABSTRACT
| FULL TEXT
Role of traditional birth attendants in preventing perinatal transmission of HIV Commentary: Involving traditional birth attendants in prevention of HIV transmission needs careful consideration
Bulterys et al.
BMJ 2002;324:222-225.
FULL TEXT
Regular review: HIV infection in children
Saloojee and Violari
BMJ 2001;323:670-674.
FULL TEXT
Two Drugs for HIV Prevention: More Benefit, More Risk
JWatch Gastroenterology 2001;2001:11-11.
FULL TEXT
AZT + 3TC in Pregnancy
AIDS Clin Care 2001;2001:3-3.
FULL TEXT
Zidovudine + Lamivudine = Less Perinatal HIV Transmission
JWatch Infect. Diseases 2001;2001:1-1.
FULL TEXT
Two Drugs for HIV Prevention: More Benefit, More Risk
JWatch General 2001;2001:7-7.
FULL TEXT
Combination Prophylaxis for Prevention of Maternal-Infant HIV Transmission: Beyond 076
Shaffer
JAMA 2001;285:2129-2131.
FULL TEXT
|
